格隆汇10月23日丨丽珠医药(01513.HK)发布公告，2025年第三季度，实现营业收入28.44亿元(人民币， 下同)，同比增长1.60%；归属于上市公司股东的净利润4.73亿元，同比下降5.73%；归属于上市公司股 东的扣除非经常性损益的净利润4.54亿元，同比下降4.58%；基本每股收益0.52元。 ...

Financial Performance - Total revenue for Q3 2025 reached RMB 2,844,001,646.29, an increase of 1.60% compared to the same period last year[6] - Net profit attributable to shareholders decreased by 5.73% to RMB 473,012,359.77 for Q3 2025[6] - Basic earnings per share for Q3 2025 was RMB 0.52, down 3.70% year-on-year[6] - For the first nine months of 2025, the company reported operating revenue of RMB 9,115,914,290.40, a slight increase from RMB 9,081,603,788.36 in the same period of 2024, representing a growth of approximately 0.38%[28] - The operating profit for the same period was RMB 2,510,927,913.36, compared to RMB 2,315,421,100.65 in 2024, indicating an increase of about 8.44%[28] - The net profit attributable to shareholders of the parent company for the first nine months of 2025 was RMB 1,754,100,316.30, up from RMB 1,672,733,989.63 in 2024, reflecting a growth of approximately 4.86%[28] - Total comprehensive income for the period (January to September 2025) reached RMB 2,071,231,848.52, an increase from RMB 1,896,000,641.95 in the same period of 2024, representing a growth of approximately 9.2%[29] - Basic and diluted earnings per share for the period were both RMB 1.96, up from RMB 1.81 in the same period last year, representing an increase of about 8.3%[29] Assets and Liabilities - Total assets as of the end of Q3 2025 amounted to RMB 24,537,984,410.75, reflecting a 0.34% increase from the previous year[8] - Total assets as of September 30, 2025, amounted to RMB 24,537,984,410.75, slightly up from RMB 24,455,825,697.18 at the beginning of the year[26] - Current assets totaled RMB 16,572,128,734.92, compared to RMB 16,419,980,644.30 at the start of the year, showing an increase of about 0.92%[26] - Total liabilities decreased to RMB 9,170,977,356.02 from RMB 9,550,079,103.14, a reduction of approximately 3.96%[27] - The company’s total equity attributable to shareholders increased by 0.73% to RMB 13,962,841,806.50[8] - The company’s total equity attributable to shareholders increased to RMB 13,962,841,806.50 from RMB 13,862,334,189.33, reflecting a growth of about 0.72%[27] Cash Flow - Cash flow from operating activities for the year-to-date period increased by 9.42% to RMB 2,525,421,252.84[6] - Net cash flow from operating activities for the period was RMB 2,525,421,252.84, compared to RMB 2,307,915,362.28 in the previous year, indicating an increase of about 9.5%[30] - Cash inflow from investment activities skyrocketed by 993.72% to 4,935,250,581.28 RMB, primarily from the maturity of structured deposits[16] - Cash outflow from investment activities increased by 508.37% to 6,561,574,810.45 RMB, mainly due to new structured deposits[16] - The net cash flow from investment activities was -1,626,324,229.17 RMB, a decrease of 159.25% compared to the previous period[16] - Net cash flow from financing activities showed a decrease, with a net outflow of RMB 1,750,752,190.63 compared to RMB 1,912,251,596.10 in the previous year, reflecting a reduction of approximately 8.4%[31] Expenses and Investments - Development expenses rose by 61.40% to RMB 355,884,300.38, mainly due to increased investment in clinical trials for the JP1366 tablet[14] - Financial expenses increased by 244.07% to -189,000,313.28 RMB due to higher interest income from deposits[15] - Investment income rose by 88.08% to 48,706,390.01 RMB, primarily from changes in the profit and loss of associated companies[15] - Fair value changes in investment income improved by 144.49% to 2,447,091.77 RMB, reflecting fluctuations in the market value of held securities[15] - Credit impairment losses surged by 2317.48% to -7,890,079.59 RMB, mainly due to increased expected credit losses on receivables[15] - Research and development expenses for the first nine months of 2025 were RMB 683,264,467.54, compared to RMB 734,493,897.75 in 2024, indicating a decrease of approximately 6.96%[28] Shareholder Information - The total number of common shareholders at the end of the reporting period was 47,362, with 47,343 being A-share shareholders[19] - The company repurchased a total of 15,376,845 A-shares, accounting for 1.70% of the total share capital, with a total expenditure of 570,228,471.25 RMB[24] - As of September 30, 2025, the company has not repurchased any H-shares[25] Cash and Cash Equivalents - The company’s cash and cash equivalents were RMB 9,918,953,931.89, down from RMB 10,827,146,984.92 at the beginning of the year, a decrease of about 8.39%[26] - The total cash and cash equivalents at the end of the period stood at RMB 9,909,534,008.29, down from RMB 10,723,355,139.50 at the end of the previous year, a decrease of approximately 7.6%[31] - Cash received from sales of goods and services was RMB 9,744,458,934.54, slightly down from RMB 9,877,413,424.19 in the previous year, a decrease of about 1.3%[30] - The company received RMB 28,799,064.00 from investments during the period, a decrease from RMB 161,751,999.95 in the previous year, reflecting a decline of approximately 82.2%[31] - The impact of exchange rate changes on cash and cash equivalents was a decrease of RMB 56,627,486.05, compared to a decrease of RMB 21,353,488.46 in the previous year, indicating a worsening of approximately 165.7%[31]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發表 任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任 何責任。 取消監事會、修訂〈公司章程〉 並辦理工商變更登記 2025年10月23日，麗珠醫藥集團股份有限公司Livzon Pharmaceutical Group Inc.* （「本公司」）召開了第十一屆董事會（「董事会」）第二十七次會議，審議通過了 《關於取消監事會、修訂〈公司章程〉並辦理工商變更登記的議案》《關於修訂〈股 東大會議事規則〉並更名的議案》及《關於修訂〈董事會議事規則〉的議案》等議案。 現將有關詳情公告如下： 一、取消監事會的相關情況 – 2 – （一）《公司章程》主要修訂前後對照表如下： | 現行條款 | 修訂後條款 | | --- | --- | | 第一條 為維護麗珠醫藥集團股份有限公司（以下 | 第一條 為維護麗珠醫藥集團股份有限公司（以下 | | 簡稱公司）、股東和債權人的合法權益，規範公司 | 簡稱公司）、股東、職工和債權人的合法權益，規 | | 的組織和行為，根據《中華人民共和國公司 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或 因倚賴該等內容而引致的任何損失承擔任何責任。 海外監管公告 茲載列麗珠醫藥集團股份有限公司於深圳證券交易所網站刊發之《麗珠醫藥集團股份有 限公司第十一屆監事會第十五次會議公告》，僅供參閱。 承董事會命 麗珠醫藥集團股份有限公司 Livzon Pharmaceutical Group Inc. * 公司秘書 劉寧 中國，珠海 二零二五年十月二十三日 於本公告日期，本公司的執行董事為唐陽剛先生 ( 總裁 ) 及徐國祥先生 ( 副董事長及副總裁 ); 本 公司的非執行董事為朱保國先生 ( 董事長 ) 、陶德勝先生 ( 副董事長 ) 、林楠棋先生及邱慶豐先 生 ; 而本公司的獨立非執行董事為白華先生、田秋生先生、黃錦華先生、羅會遠先生及崔麗 婕女士。 * 僅供識別 本公告乃根據香港聯合交易所有限公司證券上市規則第 13.10B 條而刊發。 丽珠医药集团股份有限公司（以下简称"公司"）第十一届监事会第十五次会 议于2025年10月23日以现场和通讯表决相结合 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或 因倚賴該等內容而引致的任何損失承擔任何責任。 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第 13.10B 條而刊發。 茲載列麗珠醫藥集團股份有限公司於深圳證券交易所網站刊發之《麗珠醫藥集團股份有 限公司第十一屆董事會第二十七次會議決議公告》，僅供參閱。 承董事會命 麗珠醫藥集團股份有限公司 Livzon Pharmaceutical Group Inc. * 公司秘書 劉寧 中國，珠海 二零二五年十月二十三日 於本公告日期，本公司的執行董事為唐陽剛先生 ( 總裁 ) 及徐國祥先生 ( 副董事長及副總裁 ); 本 公司的非執行董事為朱保國先生 ( 董事長 ) 、陶德勝先生 ( 副董事長 ) 、林楠棋先生及邱慶豐先 生 ; 而本公司的獨立非執行董事為白華先生、田秋生先生、黃錦華先生、羅會遠先生及崔麗 婕女士。 * 僅供識別 证券代码：000513、01513 证券简称：丽珠集团、丽珠医药 公告编号：2025-062 丽珠医药集团股份有 ...

Core Viewpoint - The news provides an overview of the upcoming IPOs, earnings announcements, shareholder meetings, and dividend distributions for various companies listed on the Hong Kong Stock Exchange as of October 23, 2025 [1]. New IPO Activities - Companies currently in the IPO process include: - Baima Tea Industry - Cambridge Technology - Sany Heavy Industry - Dipu Technology - Prada - Lijuz Pharmaceutical [1] Earnings Announcement Dates - Companies scheduled to announce earnings include: - Faraday - Ping An Good Doctor - Longyuan Power - Orient Overseas International - Qingdao Port - China Innovation Investment - Chongqing Machinery and Electric [1] Shareholder Meeting Dates - Companies holding shareholder meetings include: - Datang Power - Andeli Juice - Hongye Futures - Tibet Water Resources - China Anshun Energy [1] Dividend Distribution - Companies with upcoming dividend distributions include: - Hang Seng Bank (ex-dividend date) - Huaxun (dividend payment date) - Wansichang International (dividend payment date) - Zhifeng Industrial Electronics (dividend payment date) - Haitian Flavoring and Food (dividend payment date) - China Shipbuilding Defense (dividend payment date) - Dongfang Xingye Holdings (dividend payment date) - China Resources Mixc Life (dividend payment date) [1][3][4]

Core Viewpoint - The report by Zhiyan Consulting highlights the growth and future trends in China's chemical pharmaceutical industry, indicating a steady increase in production and market dynamics from 2025 to 2031 [1]. Industry Summary - According to the National Bureau of Statistics, the production of chemical pharmaceutical raw materials in China reached 263,000 tons in August 2025, with a cumulative production of 2,477,000 tons from January to August 2025, reflecting a growth of 3.1% [1]. - The report provides insights into the supply and demand situation in the chemical pharmaceutical industry, projecting future trends and market conditions [1]. Company Summary - Listed companies in the report include Heng Rui Medicine, East China Medicine, Lizhu Group, Baiyunshan, North China Pharmaceutical, Haizheng Pharmaceutical, Fosun Pharmaceutical, Kelun Pharmaceutical, Enhua Pharmaceutical, and Xianju Pharmaceutical, indicating a diverse range of players in the market [1]. - The report emphasizes the importance of industry research and consulting services in aiding investment decisions, showcasing Zhiyan Consulting's expertise in providing comprehensive industry solutions [1].

Core Viewpoint - The report by Zhiyan Consulting highlights the growth trends in China's chemical pharmaceutical industry, projecting a production increase in raw chemical drugs by 3.4% year-on-year in April 2025, with a cumulative growth of 3.9% from January to April 2025 [1] Industry Summary - In April 2025, China's production of raw chemical drugs reached 332,000 tons, marking a year-on-year increase of 3.4% [1] - The cumulative production of raw chemical drugs from January to April 2025 totaled 1,257,000 tons, reflecting a cumulative growth of 3.9% [1] - The report provides insights into the supply and demand dynamics of the chemical pharmaceutical industry in China from 2025 to 2031 [1] Company Summary - Listed companies in the report include Heng Rui Medicine, East China Pharmaceutical, Lijun Group, Baiyunshan, North China Pharmaceutical, Haizheng Pharmaceutical, Fosun Pharmaceutical, Kelun Pharmaceutical, Enhua Pharmaceutical, and Xianju Pharmaceutical [1] - Zhiyan Consulting is recognized as a leading industry consulting firm in China, specializing in in-depth industry research and providing comprehensive consulting services for investment decisions [1]

田秋生先生及黄锦华先生均确认其与董事会或公司并无意见分歧，亦无有关其辞任的事宜须提请公司股 东关注。截至本公告披露日，田秋生先生及黄锦华先生均未持有公司股份，不存在应当履行而未履行的 承诺事项。 田秋生先生及黄锦华先生在担任公司独立董事期间，勤勉尽责，为促进公司的规范运作发挥了积极作 用，董事会对田秋生先生及黄锦华先生在任职期间所作出的贡献表示诚挚的感谢。 特此公告。 丽珠医药集团股份有限公司董事会 2025年10月15日 登录新浪财经APP 搜索【信披】查看更多考评等级 本公司及董事会全体成员保证信息披露内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 丽珠医药集团股份有限公司（以下简称"公司"或"丽珠集团"）董事会于近日收到独立董事田秋生先生及 黄锦华先生的书面辞职报告。田秋生先生及黄锦华先生均自2019年10月15日起担任公司独立董事，截至 2025年10月15日，连续担任公司独立董事将满六年。根据《上市公司独立董事管理办法》《公司章程》 等有关规定，独立董事连任时间不得超过六年，因此田秋生先生及黄锦华先生向公司董事会提交了书面 辞职报告，田秋生先生申请辞去公司第十一届董事会独立董事、审计委 ...

为确保董事会的正常运作，在公司股东大会选举产生新任独立非执行董事前，田秋生先生及黄锦华先生 仍将按照《公司章程》《上市公司独立董事管理办法》《香港上市规则》等相关规定，继续履行独立非 执行董事及董事会各专门委员会委员的相应职责。 丽珠医药(01513)公布，董事会于近日收到独立非执行董事田秋生先生及黄锦华先生的书面辞职报告。 田秋生先生及黄锦华先生均自2019年10月15日起担任公司独立非执行董事，截至2025年10月15日，连续 担任公司独立非执行董事将满六年。根据《上市公司独立董事管理办法》《公司章程》等有关规定，独 立董事连任时间不得超过六年，因此田秋生先生及黄锦华先生向董事会提交了书面辞职报告，田秋生先 生申请辞去公司第十一届董事会独立非执行董事、审计委员会成员、薪酬与考核委员会主席、提名委员 会成员及环境、社会及管治委员会成员职务。黄锦华先生申请辞去环境、社会及管治委员会成员职务。 ...